ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Fabrazyme 35 mg powder for concentrate for solution for infusion
Fabrazyme 5 mg powder for concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Fabrazyme 35 mg powder for concentrate for solution for infusion

Each vial of Fabrazyme contains a nominal value of 35 mg of agalsidase beta. After reconstitution with 7.2 ml water for injections, each vial of Fabrazyme contains 5 mg/ml (35 mg/7 ml) of agalsidase beta. The reconstituted solution must be diluted further (see section 6.6).

Fabrazyme 5 mg powder for concentrate for solution for infusion

Each vial of Fabrazyme contains a nominal value of 5 mg of agalsidase beta. After reconstitution with 1.1 ml water for injections, each vial of Fabrazyme contains 5 mg/ml of agalsidase beta. The reconstituted solution must be diluted further (see section 6.6).

Agalsidase beta is a recombinant form of human α-galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture. The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of α-galactosidase A.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder for concentrate for solution for infusion.
White to off-white lyophilisate or powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.

4.2 Posology and method of administration

Fabrazyme treatment should be supervised by a physician experienced in the management of patients with Fabry disease or other inherited metabolic diseases.

Posology

The recommended dose of Fabrazyme is 1 mg/kg body weight administered once every 2 weeks as an intravenous infusion.

Infusion of Fabrazyme at home may be considered for patients who are tolerating their infusions well. The decision to have a patient move to home infusion should be made after evaluation and recommendation by the treating physician. Patients experiencing adverse events during the home infusion need to immediately stop the infusion process and seek the attention of a healthcare professional. Subsequent infusions may need to occur in a clinical setting. Dose and infusion rate
should remain constant while at home, and not be changed without supervision of a healthcare professional.

**Special populations**

**Renal impairment**
No dose adjustment is necessary for patients with renal insufficiency.

**Hepatic impairment**
Studies in patients with hepatic insufficiency have not been performed.

**Elderly**
The safety and efficacy of Fabrazyme in patients older than 65 years have not been established and no dosage regimen can presently be recommended in these patients.

**Paediatric population**
The safety and efficacy of Fabrazyme in children aged 0 to 7 years have not yet been established. Currently available data are described in sections 5.1 and 5.2 but no recommendation on posology can be made in children aged 5 to 7 years. No data are available in children 0 to 4 years. No dose adjustment is necessary for children 8-16 years.

For patients weighing < 30 kg, the maximum infusion rate should remain at 0.25 mg/min (15 mg/hr).

**Method of administration**

Fabrazyme should be administered as an intravenous (IV) infusion.

The initial IV infusion rate should be no more than 0.25 mg/min (15 mg/hour). The infusion rate may be slowed in the event of infusion-associated reactions.

After patient tolerance is well established, the infusion rate may be increased in increments of 0.05 to 0.083 mg/min (increments of 3 to 5 mg/hr) with each subsequent infusion. In clinical trials with classic patients, the infusion rate was increased incrementally to reach a minimum duration of 2 hours. This was achieved after 8 initial infusions at 0.25 mg/min (15 mg/hr), without any IARs, change in infusion rate, or infusion interruption. A further decrease of infusion time to 1.5 hours was allowed for patients without new IARs during the last 10 infusions or reported serious adverse events within the last 5 infusions. Each rate increment of 0.083 mg/min (~5 mg/hr) was maintained for 3 consecutive infusions, without any new IARs, change in infusion rate, or infusion interruption, before subsequent rate increases.

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

**4.3 Contraindications**

Life threatening hypersensitivity (anaphylactic reaction) to the active substance or any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

**Immunogenicity**

Since agalsidase beta (r-hαGAL) is a recombinant protein, the development of IgG antibodies is expected in patients with little or no residual enzyme activity. The majority of patients developed IgG antibodies to r-hαGAL, typically within 3 months of the first infusion with Fabrazyme. Over time, the majority of seropositive patients in clinical trials demonstrated either a downward trend in titres (based on a ≥ 4-fold reduction in titre from the peak measurement to the last measurement) (40% of
the patients), tolerised (no detectable antibodies confirmed by 2 consecutive radioimmuno-precipitation (RIP) assays) (14% of the patients) or demonstrated a plateau (35% of the patients).

**Infusion associated reactions**

Patients with antibodies to r-hαGAL have a greater potential to experience infusion-associated reactions (IARs), which are defined as any related adverse event occurring on the infusion day. These patients should be treated with caution when re-administering agalsidase beta (see section 4.8). Antibody status should be regularly monitored.

In clinical trials, sixty seven percent (67 %) of the patients experienced at least one infusion-associated reaction (see section 4.8). The frequency of IARs decreased over time. Patients experiencing mild or moderate infusion-associated reactions when treated with agalsidase beta during clinical trials have continued therapy after a reduction in the infusion rate (~0.15 mg/min; 10 mg/hr) and/or pre-treatment with antihistamines, paracetamol, ibuprofen and/or corticosteroids.

**Hypersensitivity**

As with any intravenous protein medicinal product, allergic-type hypersensitivity reactions are possible.

A small number of patients have experienced reactions suggestive of immediate (Type I) hypersensitivity. If severe allergic or anaphylactic-type reactions occur, immediate discontinuation of the administration of Fabrazyme should be considered and appropriate treatment initiated. The current medical standards for emergency treatment are to be observed. With careful rechallenge Fabrazyme has been re-administered to all 6 patients who tested positive for IgE antibodies or had a positive skin test to Fabrazyme in a clinical trial. In this trial, the initial rechallenge administration was at a low dose and a lower infusion rate (1/2 the therapeutic dose at 1/25 the initial standard recommended rate). Once a patient tolerates the infusion, the dose may be increased to reach the therapeutic dose of 1 mg/kg and the infusion rate may be increased by slowly titrating upwards, as tolerated.

**Patients with advanced renal disease**

The effect of Fabrazyme treatment on the kidneys may be limited in patients with advanced renal disease.

**Sodium**

This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

**Traceability**

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.

**4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies and no in vitro metabolism studies have been performed. Based on its metabolism, agalsidase beta is an unlikely candidate for cytochrome P450 mediated drug-drug interactions.

Fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamycin due to a theoretical risk of inhibition of intra-cellular α-galactosidase A activity.
4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of agalsidase beta in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal development (see section 5.3).

Fabrazyme should not be used during pregnancy unless clearly necessary.

Breast-feeding

Agalsidase beta may be excreted in milk. Because there are no data available on effects in neonates exposed to agalsidase beta via breast milk, it is recommended to stop breast-feeding when Fabrazyme is used.

Fertility

Studies have not been conducted to assess the potential effects of Fabrazyme on impairment of fertility.

4.7 Effects on ability to drive and use machines

Fabrazyme may have a minor influence on the ability to drive or use machines on the day of Fabrazyme administration because dizziness, somnolence, vertigo and syncope may occur (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

Since agalsidase beta (r-hαGAL) is a recombinant protein, the development of IgG antibodies is expected in patients with little or no residual enzyme activity. Patients with antibodies to r-hαGAL have a greater potential to experience infusion-associated reactions (IARs). Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of patients (see section 4.4).

Very common adverse reactions included chills, pyrexia, feeling cold, nausea, vomiting, headache and paraesthesia. Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction. Anaphylactoid reactions have been reported in the postmarketing setting.

Tabulated list of adverse reactions

Adverse reactions reported from clinical trials with a total of 168 patients (154 males and 14 females) treated with Fabrazyme administered at a dose of 1 mg/kg every 2 weeks for a minimum of one infusion up to a maximum of 5 years are listed by System Organ Class and frequency (very common ≥ 1/10; common ≥ 1/100 to < 1/10 and uncommon ≥ 1/1,000 to < 1/100) in the table below. The occurrence of an adverse reaction in a single patient is defined as uncommon in light of the relatively small number of patients treated. Adverse reactions only reported during the Post Marketing period are also included in the table below at a frequency category of “not known” (cannot be estimated from the available data). Adverse reactions were mostly mild to moderate in severity:
<table>
<thead>
<tr>
<th>System organ class</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>---</td>
<td>nasopharyngitis</td>
<td>rhinitis</td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>anaphylactoid reaction</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>headache, paraesthesia</td>
<td>dizziness, somnolence, hypoesthesia, burning sensation, lethargy, syncope</td>
<td>hyperaesthesia, tremor</td>
<td>---</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>---</td>
<td>lacrimation increased</td>
<td>eye pruritus, ocular hyperaemia</td>
<td>---</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>---</td>
<td>tinnitus, vertigo</td>
<td>auricular swelling, ear pain</td>
<td>---</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td>---</td>
<td>tachycardia, palpitations, bradycardia</td>
<td>sinus bradycardia</td>
<td>---</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>---</td>
<td>flushing, hypertension, pallor, hypotension, hot flush</td>
<td>peripheral coldness</td>
<td>---</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>---</td>
<td>dyspnoea, nasal congestion, throat tightness, wheezing, cough, dyspnoea exacerbated</td>
<td>bronchospasm, pharyngolaryngeal pain, rhinorrhoea, tachypnoea, upper respiratory tract congestion</td>
<td>hypoxia</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>nausea, vomiting</td>
<td>abdominal pain, abdominal pain upper, abdominal discomfort, stomach discomfort, hypoesthesia oral, diarrhoea</td>
<td>dyspepsia, dysphagia</td>
<td>---</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>---</td>
<td>pruritus, urticaria, rash, erythema, pruritus generalised, angioneurotic oedema, swelling face, rash maculo-papular</td>
<td>livedo reticularis, rash erythematous, rash pruritic, skin discoloration, skin discomfort</td>
<td>leukocytoclastic vasculitis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>---</td>
<td>pain in extremity, myalgia, back pain, muscle spasms, arthralgia, muscle tightness, musculoskeletal stiffness</td>
<td>musculoskeletal pain</td>
<td>---</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>chills, pyrexia, feeling cold</td>
<td>fatigue, chest discomfort, feeling hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia</td>
<td>feeling hot and cold, influenza-like illness, infusion site pain, infusion site reaction, injection site thrombosis, malaise, oedema</td>
<td>---</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
<td>oxygen saturation decreased</td>
<td></td>
</tr>
</tbody>
</table>

For the purpose of this table, ≥1% is defined as reactions occurring in 2 or more patients. Adverse reaction terminology is based upon the Medical Dictionary for Regulatory Activities (MedDRA)
Description of selected adverse reactions

Infusion associated reactions

Infusion associated reactions consisted most often of fever and chills. Additional symptoms included mild or moderate dyspnoea, hypoxia (oxygen saturation decreased), throat tightness, chest discomfort, flushing, pruritus, urticaria, face oedema, angioneurotic oedema, rhinitis, bronchospasm, tachypnoea, wheezing, hypertension, hypotension, tachycardia, palpitations, abdominal pain, nausea, vomiting, infusion-related pain including pain at the extremities, myalgia, and headache.

The infusion-associated reactions were managed by a reduction in the infusion rate together with the administration of non-steroidal anti-inflammatory medicinal products, antihistamines and/or corticosteroids. Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction. The frequency of these reactions decreased over time. The majority of these reactions can be attributed to the formation of IgG antibodies and/or complement activation. In a limited number of patients IgE antibodies were demonstrated (see section 4.4).

Paediatric population

Limited information from clinical trials suggests that the safety profile of Fabrazyme treatment in paediatric patients ages 5-7, treated with either 0.5 mg/kg every 2 weeks or 1.0 mg/kg every 4 weeks is similar to that of patients (above the age of 7) treated at 1.0 mg/kg every 2 weeks.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

In clinical trials doses up to 3 mg/kg body weight were used.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other alimentary tract and metabolism products, enzymes. ATC code: A16AB04.

Fabry disease

Fabry disease is an inherited heterogeneous and multisystemic progressive disease, that affects both males and females. It is characterised by the deficiency of α-galactosidase. Reduced or absent α-galactosidase activity results in the presence of elevated concentrations of GL-3 and its associated soluble form lyso-GL-3 in plasma and in accumulation of GL-3 in the lysosomes of many cell types including the endothelial and parenchymal cells, ultimately leading to life-threatening clinical deteriorations as a result of renal, cardiac and cerebrovascular complications.

Mechanism of action

The rationale for enzyme replacement therapy is to restore a level of enzymatic activity sufficient to clear the accumulating substrate in the organ tissues; thereby, preventing, stabilizing or reversing the progressive decline in function of these organs before irreversible damage has occurred.
After intravenous infusion, agalsidase beta is rapidly removed from the circulation and taken up by vascular endothelial and parenchymal cells into lysosomes, likely through the mannose-6 phosphate, mannose and asialoglycoprotein receptors.

Clinical efficacy and safety

Efficacy and safety of Fabrazyme was evaluated in two studies with children, one dose-finding study, two double-blind placebo-controlled studies, one open-label extension study in both male and female patients and published scientific literature.

In the dose finding study, the effects of 0.3, 1.0 and 3.0 mg/kg once every 2 weeks and 1.0 and 3.0 mg/kg once every 2 days were evaluated. A reduction in GL-3 was observed in kidney, heart, skin and plasma at all doses. Plasma GL-3 was cleared in a dose dependent manner, but was less consistent at the dose of 0.3 mg/kg. In addition, infusion-associated reactions were dose dependent.

In the first placebo-controlled clinical trial of 58 Fabry patients with classic phenotype (56 males and 2 females), Fabrazyme was effective in clearing GL-3 from the vascular endothelium of the kidney after 20 weeks of treatment. This clearance was achieved in 69% (20/29) of the Fabrazyme treated patients, but in none of the placebo patients (p<0.001). This finding was further supported by a statistically significant decrease in GL-3 inclusions in kidney, heart and skin combined and in the individual organs in patients treated with agalsidase beta compared to placebo patients (p<0.001). Sustained clearance of GL-3 from kidney vascular endothelium upon agalsidase beta treatment was demonstrated further in the open label extension of this trial. This was achieved in 47 of the 49 patients (96%) with available information at month 6, and in 8 of the 8 patients (100%) with available information at the end of the study (up to a total of 5 years of treatment). Clearance of GL-3 was also achieved in several other cell types from the kidney. Plasma GL-3 levels rapidly normalised with treatment and remained normal through 5 years.

Renal function, as measured by glomerular filtration rate and serum creatinine, as well as proteinuria, remained stable in the majority of the patients. However, the effect of Fabrazyme treatment on the kidney function was limited in some patients with advanced renal disease.

Although no specific study has been conducted to assess the effect on the neurological signs and symptoms, the results also indicate that patients may achieve reduced pain and enhanced quality of life upon enzyme replacement therapy.

Another double-blind, placebo-controlled study of 82 Fabry patients with classic phenotype (72 males and 10 females) was performed to determine whether Fabrazyme would reduce the rate of occurrence of renal, cardiac, or cerebrovascular disease or death. The rate of clinical events was substantially lower among Fabrazyme-treated patients compared to placebo-treated patients (risk reduction = 53% intent-to-treat population (p=0.0577); risk reduction = 61 % per-protocol population (p=0.0341)). This result was consistent across renal, cardiac and cerebrovascular events.

Two large observational studies followed a group of patients (n=89 to 105) who were maintained on standard-dose Fabrazyme (1.0 mg/kg every 2 weeks) or assigned to a reduced dose of Fabrazyme (0.3-0.5 mg/kg every 2 weeks) followed by a switch to agalsidase alfa (0.2 mg/kg every 2 weeks) or directly switched to agalsidase alfa (0.2 mg/kg every 2 weeks). Due to the observational, multi-centre design of these studies based in a real-world clinical setting, there are confounding factors affecting the interpretation of the results, including the selection of patients and assignment of treatment groups and available parameters between centres over time. Due to the rarity of Fabry disease, the study populations of the observational studies overlapped and the treatment groups in respective studies were small. Moreover, most patients with more severe disease, especially men, remained on standard dose Fabrazyme, whereas a treatment switch occurred more frequently in patients with less severe disease and women. Comparisons between the groups should therefore be cautiously interpreted.

The Fabrazyme standard-dose group demonstrated no significant changes in cardiac, renal, or neurologic organ function or in symptoms related to Fabry disease. Similarly, no significant changes in cardiac or neurologic function were observed in patients in the Fabrazyme dose-reduction group.
However, deterioration in renal parameters, as measured by estimated glomerular filtration rate (eGFR), was observed in patients treated with a lower dose (p<0.05). The annual decreases in eGFR were attenuated in patients who re-switched back to standard dose Fabrazyme. These results are consistent with 10-year follow-up evidence from the Canadian Fabry Disease Initiative Registry.

In the observational studies an increase in symptoms related to Fabry disease (e.g. gastrointestinal pain, diarrhoea) was observed in patients who had received a dose reduction of agalsidase beta.

Also in the postmarketing setting, experience was gained in patients who initiated Fabrazyme treatment at a dose of 1 mg/kg every 2 weeks and subsequently received a reduced dose for an extended period. In some of these patients, an increase of some of the following symptoms was spontaneously reported: pain, paraesthesia and diarrhoea, as well as cardiac, central nervous system and renal manifestations. These reported symptoms resemble the natural course of Fabry disease.

In an analysis conducted in the Fabry Registry, the incidence rates (95% confidence interval) of the first severe clinical event in Classic male Fabrazyme-treated patients with sustained anti-agalsidase beta IgG antibodies were 43.98 (18.99, 86.66), 48.60 (32.03, 70.70), and 56.07 (30.65, 94.07) per 1000 person-years in the low, medium, and high peak titre groups, respectively. These observed differences were not statistically significant.

**Paediatric population**

In one open-label paediatric study, sixteen patients with Fabry disease (8-16 years old; 14 males, 2 females) had been treated for one year at 1.0 mg/kg every 2 weeks. Clearance of GL-3 in the superficial skin vascular endothelium was achieved in all patients who had accumulated GL-3 at baseline. The 2 female patients had little or no GL-3 accumulation in the superficial skin vascular endothelium at baseline, making this conclusion applicable in male patients only.

In an additional 5-year open-label paediatric study, 31 male patients aged 5 to 18 years were randomised prior to the onset of clinical symptoms involving major organs and treated with two lower dose regimens of agalsidase beta, 0.5 mg/kg every 2 weeks or 1.0 mg/kg every 4 weeks. Results were similar between the two treatment groups. Superficial skin capillary endothelium GL-3 scores were reduced to zero or maintained at zero at all time points post-baseline upon treatment in 19/27 patients completing the study without a dose increase. Both baseline and 5-year kidney biopsies were obtained in a subset of 6 patients: in all, kidney capillary endothelium GL-3 scores were reduced to zero but highly variable effects were observed in podocyte GL-3, with a reduction in 3 patients. Ten (10) patients met per protocol dose increase criteria, two (2) had a dose increase to the recommended dose of 1.0 mg/kg every 2 weeks.

**5.2 Pharmacokinetic properties**

Following an intravenous administration of agalsidase beta to adults at doses of 0.3 mg, 1 mg and 3 mg/kg body weight, the AUC values increased more than dose proportional, due to a decrease in clearance, indicating a saturated clearance. The elimination half-life was dose independent and ranged from 45 to 100 minutes.

After intravenous administration of agalsidase beta to adults with an infusion time of approximately 300 minutes and at a dose of 1 mg/kg body weight, biweekly, mean $C_{\text{max}}$ plasma concentrations ranged from 2000-3500 ng/ml, while the $AUC_{\text{inf}}$ ranged from 370-780 µg min/ml. Vss ranged from 8.3-40.8 l, plasma clearance from 119-345 ml/min and the mean elimination half-life from 80-120 minutes.

Agalsidase beta is a protein and is expected to be metabolically degraded through peptide hydrolysis. Consequently, impaired liver function is not expected to affect the pharmacokinetics of agalsidase beta in a clinically significant way. Renal elimination of agalsidase beta is considered to be a minor pathway for clearance.
Paediatric population

Fabrazyme pharmacokinetics was also evaluated in two paediatric studies. In one of these studies, 15 paediatric patients with available pharmacokinetics data, aged 8.5 to 16 years weighing 27.1 to 64.9 kg were treated with 1.0 mg/kg every 2 weeks. Agalsidase beta clearance was not influenced by weight in this population. Baseline CL was 77 ml/min with a Vss of 2.6 l; half-life was 55 min. After IgG seroconversion, CL decreased to 35 ml/min, Vss increased to 5.4 l, and half-life increased to 240 min. The net effect of these changes after seroconversion was an increase in exposure of 2- to 3-fold based on AUC and C\text{max}. No unexpected safety issues were encountered in patients with an increase in exposure after seroconversion.

In another study with 30 paediatric patients with available pharmacokinetics data, aged 5 to 18 years, treated with two lower dose regimens of 0.5 mg/kg every 2 weeks and 1.0 mg/kg every 4 weeks, mean CL was 4.6 and 2.3 ml/min/kg, respectively, mean Vss was 0.27 and 0.22 l/kg, respectively, and mean elimination half-life was 88 and 107 minutes, respectively. After IgG seroconversion, there was no apparent change in CL (+24% and +6%, resp.), while Vss was 1.8 and 2.2 fold higher, with the net effect being a small decrease in C\text{max} (up to -34% and -11%, resp.) and no change in AUC (-19% and -6%, resp.).

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, single dose toxicity, repeated dose toxicity and embryonal/foetal toxicity. Studies with regard to other stages of the development have not been carried out. Genotoxic and carcinogenic potential are not expected.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol (E421)
Sodium dihydrogen phosphate monohydrate (E339)
Disodium phosphate heptahydrate (E339)

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products in the same infusion.

6.3 Shelf life

3 years.

Reconstituted and diluted solutions

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage and conditions of the medicinal product prior to use are the responsibility of the user. The reconstituted solution cannot be stored and should be promptly diluted; only the diluted solution can be held for up to 24 hours at 2°C-8°C.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Fabrazyme 35 mg powder for concentrate for solution for infusion
Fabrazyme 35 mg is supplied in clear Type I glass 20 ml vials. The closure consists of a siliconised butyl stopper and an aluminium seal with a plastic flip-off cap.

Package sizes: 1, 5 and 10 vials per carton.
Not all pack sizes may be marketed.

Fabrazyme 5 mg powder for concentrate for solution for infusion

Fabrazyme 5 mg is supplied in clear Type I glass 5 ml vials. The closure consists of a siliconised butyl stopper and an aluminium seal with a plastic flip-off cap.

Package sizes: 1, 5 and 10 vials per carton.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride solution for injection and then administered by intravenous infusion. Aseptic technique should be used.

The number of vials should be determined to be reconstituted based on the individual patient’s weight and the required vials should be removed from the refrigerator in order to allow them to reach room temperature (in approximately 30 minutes). Each vial of Fabrazyme is intended for single use only.

Reconstitution

Fabrazyme 35 mg powder for concentrate for solution for infusion

Each vial of Fabrazyme 35 mg has to be reconstituted with 7.2 ml water for injections. Forceful impact of the water for injections on the powder and foaming should be avoided. This is done by slow drop-wise addition of the water for injection down the inside of the vial and not directly onto the lyophilisate. Each vial should be rolled and tilted gently. The vial should not be inverted, swirled or shaken.

Fabrazyme 5 mg powder for concentrate for solution for infusion

Each vial of Fabrazyme 5 mg has to be reconstituted with 1.1 ml water for injections. Forceful impact of the water for injections on the powder and foaming should be avoided. This is done by slow drop-wise addition of the water for injection down the inside of the vial and not directly onto the lyophilisate. Each vial should be rolled and tilted gently. The vial should not be inverted, swirled or shaken.

The reconstituted solution contains 5 mg agalsidase beta per ml, and appears as a clear colourless solution. The pH of the reconstituted solution is approximately 7.0. Before further dilution, the reconstituted solution in each vial should be visually inspected for particulate matter and discoloration. The solution should not be used if foreign particles are observed or if the solution is discoloured.

After reconstitution, it is recommended to promptly dilute the vials, to minimise protein particle formation over time.

Dilution

Fabrazyme 35 mg powder for concentrate for solution for infusion
Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride solution for injection, from the infusion bag.

The airspace within the infusion bag should be removed to minimise the air/liquid interface.

7.0 ml (equal to 35 mg) of the reconstituted solution from each vial up to the total volume required should be slowly withdrawn for the patient dose. Filter needles should not be used and foaming should be avoided.

The reconstituted solution should slowly be injected directly into the 0.9% sodium chloride solution for injection (not in any remaining airspace) to a final concentration between 0.05 mg/ml and 0.7 mg/ml. The total volume of sodium chloride 0.9% solution for infusion (between 50 and 500 ml) should be determined based on the individual dose. For doses lower than 35 mg a minimum of 50 ml should be used, for doses 35 to 70 mg a minimum of 100 ml should be used, for doses 70 to 100 mg a minimum of 250 ml should be used and for doses greater than 100 mg only 500 ml should be used. The infusion bag should be gently inverted or lightly massaged to mix the diluted solution. The infusion bag should not be shaken or excessively agitated.

**Fabrazyme 5 mg powder for concentrate for solution for infusion**

Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride solution for injection, from the infusion bag.

The airspace within the infusion bag should be removed to minimise the air/liquid interface.

1.0 ml (equal to 5 mg) of the reconstituted solution from each vial up to the total volume required should be slowly withdrawn for the patient dose. Filter needles should not be used and foaming should be avoided.

The reconstituted solution should slowly be injected directly into the 0.9% sodium chloride solution for injection (not in any remaining airspace) to a final concentration between 0.05 mg/ml and 0.7 mg/ml. The total volume of sodium chloride 0.9% solution for infusion (between 50 and 500 ml) should be determined based on the individual dose. For doses lower than 35 mg a minimum of 50 ml should be used, for doses 35 to 70 mg a minimum of 100 ml should be used, for doses 70 to 100 mg a minimum of 250 ml should be used and for doses greater than 100 mg only 500 ml should be used. The infusion bag should be gently inverted or lightly massaged to mix the diluted solution. The infusion bag should not be shaken or excessively agitated.

**Administration**

It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity. The initial IV infusion rate should be no more than 0.25 mg/min (15 mg/hour). The infusion rate may be slowed in the event of infusion-associated reactions.

After patient tolerance is well established, the infusion rate may be increased in increments of 0.05 to 0.083 mg/min (increments of 3 to 5 mg/hr) with each subsequent infusion. In clinical trials with classic patients, the infusion rate was increased incrementally to reach a minimum duration of 2 hours. This was achieved after 8 initial infusions at 0.25 mg/min (15 mg/hr), without any IARs, change in infusion rate, or infusion interruption. A further decrease of infusion time to 1.5 hours was allowed for patients without new IARs during the last 10 infusions or reported serious adverse events within the last 5 infusions. Each rate increment of 0.083 mg/min (~5 mg/hr) was maintained for 3 consecutive infusions, without any new IARs, change in infusion rate, or infusion interruption, before subsequent rate increases.

For patients weighing < 30 kg, the maximum infusion rate should remain at 0.25 mg/min (15 mg/hr).
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

8. MARKETING AUTHORISATION NUMBERS

EU/1/01/188/001
EU/1/01/188/002
EU/1/01/188/003
EU/1/01/188/004
EU/1/01/188/005
EU/1/01/188/006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 03 August 2001
Date of last renewal: 03 August 2006

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Genzyme Corporation
8, 45, 68, 74, 80 New York Avenue
Framingham
MA 01701
United States

Name and address of the manufacturer responsible for batch release

Genzyme Ireland Limited
IDA Industrial Park
Old Kilmeaden Road
Waterford
Ireland

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
Additional risk minimisation measures

Prior to the use of Fabrazyme in each Member State in the home setting the MAH must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The MAH shall ensure that in each Member State where Fabrazyme is marketed, all Healthcare Professionals (HCP) who are expected to prescribe Fabrazyme are provided with the following educational pack which includes HCP and Patient/Caregiver guides.

HCP Educational Material:
HCPs’ educational materials include the following elements:
- The HCP’s guide
- The Summary of Product Characteristics

HCP guide:
In order to minimise the risk of hypersensitivity reactions and medication errors in the home infusion setting, the HCP’s guide contains the following key safety information to support HCPs (prescribing and/or administering Fabrazyme) in the management of patients receiving Fabrazyme in the home setting:

Information for HCPs prescribing FABRAZYME:
- Information on the risk of medication errors potentially related to the use of Fabrazyme in the home setting,
- Criteria to determine eligibility for home infusion,
- Use of the logbook,
- Information on the need to provide the patients material to all patients receiving home infusions of Fabrazyme.

Information for HCPs administering FABRAZYME:
- Information on the risk of medication errors potentially related to the use of Fabrazyme in the home setting with focus on the actions needed to prevent medication errors that may occur in the home setting,
- Information on the risk of hypersensitivity reactions including the signs and symptoms of hypersensitivity and the recommended actions when symptoms occur,
- Use of the logbook,
- Information on the preparation and administration of Fabrazyme infusion,
- Training on the preparation and administration of Fabrazyme infusion (for patients who are going to self administer the medicinal product),
- Information on the need to provide the patients material to all patients receiving home infusions of Fabrazyme.

Patient Educational Material:
The patients’ educational materials include the following elements:
- The patient’s guide
- The patient information leaflet.

Patient guide:
The patient’s guide contains the following elements:
- Information on the risk of hypersensitivity reactions including the signs and symptoms of hypersensitivity and the recommended actions when symptoms occur,
- Use of the logbook,
- Clear step by step instructions on the reconstitution and administration of the medicinal product (only applicable to those who self-administer).
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON (1 VIAL, 5 VIALS, 10 VIALS)

1. NAME OF THE MEDICINAL PRODUCT

Fabrazyme 35 mg powder for concentrate for solution for infusion
agalsidase beta

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial of Fabrazyme contains a nominal value of 35 mg of agalsidase beta. After reconstitution with 7.2 ml water for injections, each vial of Fabrazyme contains 5 mg/ml (35 mg/7 ml) of agalsidase beta.

3. LIST OF EXCIPIENTS

mannitol (E421)
sodium dihydrogen phosphate monohydrate (E339)
disodium phosphate heptahydrate (E339)
See the leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

powder for concentrate for solution for infusion

1 vial of powder for concentrate for solution for infusion,
5 vials of powder for concentrate for solution for infusion,
10 vials of powder for concentrate for solution for infusion.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only.
Read the package leaflet before use.
Intravenous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2°C – 8°C).

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Any unused solution should be discarded.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/01/188/001 1 vial of powder for concentrate for solution for infusion
EU/1/01/188/002 5 vials of powder for concentrate for solution for infusion
EU/1/01/188/003 10 vials of powder for concentrate for solution for infusion

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fabrazyme 35 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
VIAL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

   Fabrazyme 35 mg powder for concentrate for solution for infusion
   agalsidase beta
   Intravenous use.

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

   EXP

4. BATCH NUMBER

   Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

   Store in a refrigerator (2°C – 8°C).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON (1 VIAL, 5 VIALS, 10 VIALS)

1. NAME OF THE MEDICINAL PRODUCT

Fabrazyme 5 mg powder for concentrate for solution for infusion
galsidase beta

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial of Fabrazyme contains a nominal value of 5 mg of agalsidase beta. After reconstitution with
1.1 ml water for injections, each vial of Fabrazyme contains 5 mg/ml of agalsidase beta.

3. LIST OF EXCIPIENTS

mannitol (E421)
sodium dihydrogen phosphate monohydrate (E339)
disodium phosphate heptahydrate (E339)
See the leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

powder for concentrate for solution for infusion

1 vial of powder for concentrate for solution for infusion,
5 vials of powder for concentrate for solution for infusion,
10 vials of powder for concentrate for solution for infusion.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only.
Read the package leaflet before use.
Intravenous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

Store in a refrigerator (2°C – 8°C).

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Any unused solution should be discarded.

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/01/188/004 1 vial of powder for concentrate for solution for infusion
EU/1/01/188/005 5 vials of powder for concentrate for solution for infusion
EU/1/01/188/006 10 vials of powder for concentrate for solution for infusion

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Fabrazyme 5 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER – HUMAN READABLE DATA**

PC
SN
NN
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Fabrazyme 5 mg powder for concentrate for solution for infusion
agalsidase beta
Intravenous use.

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

Store in a refrigerator (2°C – 8°C)
B. PACKAGE LEAFLET
Package leaflet: Information for the user

Fabrazyme 35 mg powder for concentrate for solution for infusion
agalsidase beta

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Fabrazyme is and what it is used for
2. What you need to know before you use Fabrazyme
3. How to use Fabrazyme
4. Possible side effects
5. How to store Fabrazyme
6. Contents of the pack and other information

1. What Fabrazyme is and what it is used for

Fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in Fabry disease, where the level of α-galactosidase enzyme activity is absent or lower than normal. If you suffer from Fabry disease a fat substance, called globotriaosylceramide (GL-3), is not removed from the cells of your body and starts to accumulate in the walls of the blood vessels of your organs.

Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.

Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.

2. What you need to know before you use Fabrazyme

Do not use Fabrazyme
- if you are allergic to agalsidase beta or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before using Fabrazyme.

If you are treated with Fabrazyme, you may develop infusion associated reactions. An infusion-associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4). If you experience a reaction like this, you should tell your doctor immediately. You may need to be given additional medicines to prevent such reactions from occurring.

Children and adolescents
No clinical studies have been performed in children 0-4 years old. The risks and benefits of Fabrazyme in children aged 5 to 7 years have not yet been established and therefore no dose can be recommended for this age group.
Other medicines and Fabrazyme
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor if you use any medicines containing chloroquine, amiodarone, benoquin or gentamicin. There is a theoretical risk of decreased agalsidase beta activity.

Pregnancy, breast-feeding and fertility
Use of Fabrazyme during pregnancy is not recommended. There is no experience with the use of Fabrazyme in pregnant women. Fabrazyme may get into breast milk. Use of Fabrazyme during breast-feeding is not recommended. Studies have not been performed to examine the effects of Fabrazyme on fertility.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
Do not drive or use machines if you experience dizziness, sleepiness, vertigo or fainting during or shortly after administration of Fabrazyme (see section 4). Talk to your doctor first.

Fabrazyme contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

3. How to use Fabrazyme

Fabrazyme is given through a drip into a vein (by intravenous infusion). It is supplied as a powder which will be mixed with sterile water before it is given (see information for Health Care Professionals at the end of this leaflet).
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Fabrazyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Fabry disease. Your doctor may advise that you can be treated at home provided you meet certain criteria. Please contact your doctor if you would like to be treated at home.

The recommended dose of Fabrazyme for adults is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

Use in children and adolescents
The recommended dose of Fabrazyme for children and adolescents 8 – 16 years is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

If you use more Fabrazyme than you should
Doses up to 3 mg/kg body weight have shown to be safe.

If you forget to use Fabrazyme
If you have missed an infusion of Fabrazyme, please contact your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical studies side effects were mainly seen while patients were being given the medicine or shortly after (“infusion related reactions”). Severe life-threatening allergic reactions (“anaphylactoid
“reactions”) have been reported in some patients. If you experience any serious side effect, you should contact your doctor immediately.

Very common symptoms (may affect more than 1 in 10 people) include chills, fever, feeling cold, nausea, vomiting, headache and abnormal feelings in the skin such as burning or tingling. Your doctor may decide to lower the infusion rate or give you additional medicines to prevent such reactions from occurring.

List of other side effects:

**Common (may affect up to 1 in 10 people):**
- chest pain
- difficulty in breathing
- pallor
- itching
- abnormal tear secretion
- feeling weak
- tinnitus
- nasal congestion
- diarrhoea
- redness
- muscle pain
- increased blood pressure
- sudden swelling of the face or throat
- oedema in extremities
- vertigo
- stomach discomfort
- muscle spasms
- sleeping
- increased heart beat
- abdominal pain
- back pain
- rash
- low heart rate
- lethargy
- syncopal
- cough
- abdominal discomfort
- swelling face
- joint pain
- decreased blood pressure
- chest discomfort
- face oedema
- exacerbated difficulty in breathing
- muscle tightness
- fatigue
- flushing
- pain
- throat tightness
- dizziness
- palpitations
- decreased sensitivity to pain
- burning sensation
- wheezing
- urticaria
- pain at the extremities
- nasopharyngitis
- hot flush
- feeling hot
- hyperthermia
- decreased mouth sensitivity
- musculoskeletal stiffness

**Uncommon (may affect up to 1 in 100 people):**
- tremor
- red eyes
- ear pain
- throat pain
- fast breathing
- itchy rash
- feeling hot and cold
- difficulty swallowing
- infusion site pain
- infusion site reaction
- itching eyes
- ear swelling
- bronchospasm
- runny nose
- heart burn
- skin discomfort
- musculoskeletal pain
- rhinitis
- influenza-like illness
- malaise
- low heart rate due to conduction disturbances
- increased sensitivity to pain
- upper respiratory tract congestion
- red rash
- (mottled purplish) skin discolouration
- coldness of the extremities
- injection site blood clotting
- skin discolouration
- oedema

**Not known (frequency cannot be estimated from the available data):**
- lower blood oxygen levels
- serious inflammation of the vessels

In some patients initially treated at the recommended dose, and whose dose was later reduced for an extended period, some symptoms of Fabry disease were reported more frequently.

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system.
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Fabrazyme

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after ‘EXP’. The expiry date refers to the last day of that month.

_Unopened vials_  
Store in a refrigerator (2°C – 8°C).

_Reconstituted and diluted solutions_  
The reconstituted solution cannot be stored and should be promptly diluted. The diluted solution can be held for up to 24 hours at 2°C – 8°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

**What Fabrazyme contains**
- The active substance is agalsidase beta, one vial contains 35 mg. After reconstitution each vial contains 5 mg of agalsidase beta per ml.
- The other ingredients are:
  - Mannitol (E421)
  - Sodium dihydrogen phosphate monohydrate (E339)
  - Disodium phosphate heptahydrate (E339).

**What Fabrazyme looks like and contents of the pack**  
Fabrazyme is supplied as a white to off-white powder. After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted. Package sizes: 1, 5 and 10 vials per carton. Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

**Marketing authorisation holder**  
Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

**Manufacturer**  
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Company</th>
<th>Tél/Tel</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien/Luxembourg</td>
<td>Sanofi Belgium</td>
<td>+ 32 2 710 54 00</td>
</tr>
<tr>
<td>България</td>
<td>Swixx Biopharma EOOD</td>
<td>+359 (0)2 4942 480</td>
</tr>
<tr>
<td>Česká republika</td>
<td>sanofi-aventis, s.r.o.</td>
<td>+420 233 086 111</td>
</tr>
<tr>
<td>Danmark</td>
<td>Sanofi A/S</td>
<td>+45 45 16 70 00</td>
</tr>
<tr>
<td>Deutschland</td>
<td>Sanofi-Aventis Deutschland GmbH</td>
<td>0800 04 36 996</td>
</tr>
<tr>
<td></td>
<td>Tel. aus dem Ausland: +49 69 305 70 13</td>
<td></td>
</tr>
<tr>
<td>Eesti</td>
<td>Swixx Biopharma OÜ</td>
<td>+372 640 10 30</td>
</tr>
<tr>
<td>Ελλάδα</td>
<td>Sanofi-Aventis Μονοπρόσωπη ΑΕΒΕ</td>
<td>+30 210 900 1600</td>
</tr>
<tr>
<td>España</td>
<td>sanofi-aventis, S.A.</td>
<td>34 93 485 94 00</td>
</tr>
<tr>
<td>France</td>
<td>Sanofi Winthrop Industrie</td>
<td>0 800 222 555</td>
</tr>
<tr>
<td></td>
<td>Appel depuis l’étranger: +33 1 57 63 23 23</td>
<td></td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Swixx Biopharma d.o.o.</td>
<td>+385 1 2078 500</td>
</tr>
<tr>
<td>Ireland</td>
<td>sanofi-aventis Ireland Ltd. T/A SANOFI</td>
<td>+353 (0) 1 403 56 00</td>
</tr>
<tr>
<td>Ísland</td>
<td>Vistor hf.</td>
<td>354 535 7000</td>
</tr>
<tr>
<td>Italia</td>
<td>Sanofi S.r.l.</td>
<td>800536389</td>
</tr>
<tr>
<td>Lietuva</td>
<td>Swixx Biopharma UAB</td>
<td>+370 5 236 91 40</td>
</tr>
<tr>
<td>Magyarország</td>
<td>SANOFI-AVENTIS Zrt.</td>
<td>+36 1 505 0050</td>
</tr>
<tr>
<td>Malta</td>
<td>Sanofi S.r.l.</td>
<td>+39 02 39394275</td>
</tr>
<tr>
<td>Nederland</td>
<td>Sanofi B.V.</td>
<td>+31 20 245 4000</td>
</tr>
<tr>
<td>Norge</td>
<td>sanofi-aventis Norge AS</td>
<td>+ 47 67 10 71 00</td>
</tr>
<tr>
<td>Österreich</td>
<td>sanofi-aventis GmbH</td>
<td>+ 43 1 80 185 - 0</td>
</tr>
<tr>
<td>Polska</td>
<td>sanofi-aventis Sp. z o.o.</td>
<td>+48 22 280 00 00</td>
</tr>
<tr>
<td>Portugal</td>
<td>Sanofi – Produtos Farmacêuticos, Lda.</td>
<td>+351 21 35 89 400</td>
</tr>
<tr>
<td>România</td>
<td>Sanofi Romania SRL</td>
<td>+40 (0) 21 317 31 36</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Swixx Biopharma d.o.o.</td>
<td>+386 1 235 51 00</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Swixx Biopharma s.r.o.</td>
<td>+421 2 208 33 600</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Sanofi Oy</td>
<td>+ 358 201 200 300</td>
</tr>
<tr>
<td>Sverige</td>
<td>Sanofi AB</td>
<td>+46 (0)8 634 50 00</td>
</tr>
</tbody>
</table>
The following information is intended for healthcare professionals only:

Instructions for use – reconstitution, dilution and administration

The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride solution for injection and then administered by intravenous infusion.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage and conditions are the responsibility of the user. The reconstituted solution cannot be stored and should be promptly diluted; only the diluted solution can be held for up to 24 hours at 2°C -8°C.

Use aseptic technique

1. The number of vials should be determined to be reconstituted based on the individual patient’s weight and the required vials should be removed from the refrigerator in order to allow them to reach room temperature (in approximately 30 minutes). Each vial of Fabrazyme is intended for single use only.

Reconstitution

2. Each vial of Fabrazyme 35 mg has to be reconstituted with 7.2 ml water for injections. Forceful impact of the water for injections on the powder and foaming should be avoided. This is done by slow drop-wise addition of the water for injection down the inside of the vial and not directly onto the lyophilisate. Each vial should be rolled and tilted gently. The vial should not be inverted, swirled or shaken.

3. The reconstituted solution contains 5 mg agalsidase beta per ml, and appears as a clear colourless solution. The pH of the reconstituted solution is approximately 7.0. Before further dilution, the reconstituted solution in each vial should be visually inspected for particulate matter and discolouration. The solution should not be used if foreign particles are observed or if the solution is discoloured.

4. After reconstitution, it is recommended to promptly dilute the vials, to minimise protein particle formation over time.

5. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
**Dilution**

6. Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride solution for injection, from the infusion bag.

7. The airspace within the infusion bag should be removed to minimise the air/liquid interface.

8. 7.0 ml (equal to 35 mg) of the reconstituted solution from each vial up to the total volume required should be slowly withdrawn for the patient dose. Filter needles should not be used and foaming should be avoided.

9. The reconstituted solution should slowly be injected directly into the 0.9% sodium chloride solution for injection (not in any remaining airspace) to a final concentration between 0.05 mg/ml and 0.7 mg/ml. The total volume of sodium chloride 0.9% solution for infusion (between 50 and 500 ml) should be determined based on the individual dose. For doses lower than 35 mg a minimum of 50 ml should be used, for doses 35 to 70 mg a minimum of 100 ml should be used, for doses 70 to 100 mg a minimum of 250 ml should be used and for doses greater than 100 mg only 500 ml should be used. The infusion bag should be gently inverted or lightly massaged to mix the diluted solution. The infusion bag should not be shaken or excessively agitated.

**Administration**

10. It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity. The initial IV infusion rate should be no more than 0.25 mg/min (15 mg/hour). The infusion rate may be slowed in the event of infusion-associated reactions.

    After patient tolerance is well established, the infusion rate may be increased in increments of 0.05 to 0.083 mg/min (increments of 3 to 5 mg/hr) with each subsequent infusion. In clinical trials with classic patients, the infusion rate was increased incrementally to reach a minimum of 2 hours. This was achieved after 8 initial infusions at 0.25 mg/min (15 mg/hr), without any IARs, change in infusion rate, or infusion interruption. A further decrease of infusion time to 1.5 hours was allowed for patients without new IARs during the last 10 infusions or reported serious adverse events within the last 5 infusions. Each rate increment of 0.083 mg/min (~5 mg/hr) was maintained for 3 consecutive infusions, without any new IARs, change in infusion rate, or infusion interruption, before subsequent rate increases.

    For patients weighing < 30 kg, the maximum infusion rate should remain at 0.25 mg/min (15 mg/hr).
Fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in Fabry disease, where the level of α-galactosidase enzyme activity is absent or lower than normal. If you suffer from Fabry disease a fat substance, called globotriaosyleramide (GL-3), is not removed from the cells of your body and starts to accumulate in the walls of the blood vessels of your organs.

Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.

Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.

2. What you need to know before you use Fabrazyme

Do not use Fabrazyme
- if you are allergic to agalsidase beta or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before using Fabrazyme.

If you are treated with Fabrazyme, you may develop infusion associated reactions. An infusion-associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4). If you experience a reaction like this, you should tell your doctor immediately. You may need to be given additional medicines to prevent such reactions from occurring.

Children and adolescents
No clinical studies have been performed in children 0-4 years old. The risks and benefits of Fabrazyme in children aged 5 to 7 years have not yet been established and therefore no dose can be recommended for this age group.
Other medicines and Fabrazyme
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor if you use any medicines containing chloroquine, amiodarone, benoquin or gentamicin. There is a theoretical risk of decreased agalsidase beta activity.

Pregnancy, breast-feeding and fertility
Use of Fabrazyme during pregnancy is not recommended. There is no experience with the use of Fabrazyme in pregnant women. Fabrazyme may get into breast milk. Use of Fabrazyme during breast-feeding is not recommended. Studies have not been performed to examine the effects of Fabrazyme on fertility.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
Do not drive or use machines if you experience dizziness, sleepiness, vertigo or fainting during or shortly after administration of Fabrazyme (see section 4). Talk to your doctor first.

Fabrazyme contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

3. How to use Fabrazyme

Fabrazyme is given through a drip into a vein (by intravenous infusion). It is supplied as a powder which will be mixed with sterile water before it is given (see information for Health Care Professionals at the end of this leaflet).
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Fabrazyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Fabry disease. Your doctor may advise that you can be treated at home provided you meet certain criteria. Please contact your doctor if you would like to be treated at home.

The recommended dose of Fabrazyme for adults is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

Use in children and adolescents
The recommended dose of Fabrazyme for children and adolescents 8 – 16 years is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

If you use more Fabrazyme than you should
Doses up to 3 mg/kg body weight have shown to be safe.

If you forget to use Fabrazyme
If you have missed an infusion of Fabrazyme, please contact your doctor.
If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical studies side effects were mainly seen while patients were being given the medicine or shortly after (“infusion related reactions”). Severe life-threatening allergic reactions (“anaphylactoid
reactions”) have been reported in some patients. If you experience any serious side effect, you should contact your doctor immediately.

Very common symptoms (may affect more than 1 in 10 people) include chills, fever, feeling cold, nausea, vomiting, headache and abnormal feelings in the skin such as burning or tingling. Your doctor may decide to lower the infusion rate or give you additional medicines to prevent such reactions from occurring.

List of other side effects:

Common (may affect up to 1 in 10 people):
- chest pain
- difficulty in breathing
- pallor
- itching
- abnormal tear secretion
- feeling weak
- tinnitus
- nasal congestion
- diarrhoea
- redness
- muscle pain
- increased blood pressure
- sudden swelling of the face or throat
- oedema in extremities
- vertigo
- stomach discomfort
- muscle spasms
- sleepiness
- increased heart beat
- abdominal pain
- back pain
- rash
- low heart rate
- lethargy
- syncope
- cough
- abdominal discomfort
- swelling face
- joint pain
- decreased blood pressure
- chest discomfort
- face oedema
- exacerbated difficulty in breathing
- muscle tightness
- fatigue
- flushing
- pain
- throat tightness
- dizziness
- palpitations
- decreased sensitivity to pain
- burning sensation
- wheezing
- urticaria
- pain at the extremities
- nasopharyngitis
- hot flush
- feeling hot
- hyperthermia
- decreased mouth sensitivity
- musculoskeletal stiffness

Uncommon (may affect up to 1 in 100 people):
- tremor
- red eyes
- ear pain
- throat pain
- fast breathing
- itchy rash
- feeling hot and cold
- difficulty swallowing
- infusion site pain
- infusion site reaction
- itching eyes
- ear swelling
- bronchospasm
- runny nose
- heart burn
- skin discomfort
- musculoskeletal pain
- rhinitis
- influenza-like illness
- malaise
- low heart rate due to conduction disturbances
- increased sensitivity to pain
- upper respiratory tract congestion
- red rash
- (mottled purplish) skin discoloration
- coldness of the extremities
- injection site blood clotting
- skin discoloration
- oedema

Not known (frequency cannot be estimated from the available data):
- lower blood oxygen levels
- serious inflammation of the vessels

In some patients initially treated at the recommended dose, and whose dose was later reduced for an extended period, some symptoms of Fabry disease were reported more frequently.

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system.
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Fabrazyme

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after ‘EXP’. The expiry date refers to the last day of that month.

*Unopened vials*
Store in a refrigerator (2°C – 8°C).

*Reconstituted and diluted solutions*
The reconstituted solution cannot be stored and should be promptly diluted. The diluted solution can be held for up to 24 hours at 2°C – 8°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

*What Fabrazyme contains*  
- The active substance is agalsidase beta, one vial contains 5 mg. After reconstitution each vial contains 5 mg agalsidase beta per ml.
- The other ingredients are:
  - Mannitol (E421)
  - Sodium dihydrogen phosphate monohydrate (E339)
  - Disodium phosphate heptahydrate (E339).

*What Fabrazyme looks like and contents of the pack*  
Fabrazyme is supplied as a white to off-white powder. After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted.

Package sizes: 1, 5 and 10 vials per carton. Not all pack sizes may be marketed.

*Marketing Authorisation Holder and Manufacturer*  

**Marketing authorisation holder**  
Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

**Manufacturer**  
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien/Luxembourg</td>
<td>Sanofi Belgium</td>
<td>Tél/Tel: +32 2 710 54 00</td>
</tr>
<tr>
<td>België/Belgique/Belgien/Luxembourg</td>
<td>Swixx Biopharma UAB</td>
<td>Tel: +370 5 236 91 40</td>
</tr>
<tr>
<td>България</td>
<td>Swixx Biopharma EOOD</td>
<td>Tel.: +359 (0)2 4942 480</td>
</tr>
<tr>
<td>Malta</td>
<td>Sanofi S.r.l.</td>
<td>Tel: +39 02 39394275</td>
</tr>
<tr>
<td>Danmark</td>
<td>Sanofi A/S</td>
<td>Tlf: +45 45 16 70 00</td>
</tr>
<tr>
<td>Nederland</td>
<td>Sanofi B.V.</td>
<td>Tel: +31 20 245 4000</td>
</tr>
<tr>
<td>Deutschl Land</td>
<td>Sanofi-Aventis Deutschland GmbH</td>
<td>Tel.: 0800 04 36 996</td>
</tr>
<tr>
<td>Deutschl Land</td>
<td>Tel. aus dem Ausland: +49 69 305 70 13</td>
<td></td>
</tr>
<tr>
<td>Česká republika</td>
<td>sanofi-aventis, s.r.o.</td>
<td>Tel: +420 233 086 111</td>
</tr>
<tr>
<td>Österreich</td>
<td>sanofi-aventis GmbH</td>
<td>Tel: +43 1 80 185 - 0</td>
</tr>
<tr>
<td>España</td>
<td>sanofi-aventis, S.A.</td>
<td>Tel: +34 93 485 94 00</td>
</tr>
<tr>
<td>Polska</td>
<td>sanofi-aventis Sp. z o.o.</td>
<td>Tel.: +48 22 280 00 00</td>
</tr>
<tr>
<td>France</td>
<td>Sanofi Winthrop Industrie</td>
<td>Tél: 0 800 222 555</td>
</tr>
<tr>
<td></td>
<td>Appel depuis l’étranger: +33 1 57 63 23 23</td>
<td></td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Swixx Biopharma d.o.o.</td>
<td>Tel: +385 1 2078 500</td>
</tr>
<tr>
<td>Ireland</td>
<td>sanofi-aventis Ireland Ltd. T/A SANOFI</td>
<td>Tel: +353 (0) 1 403 56 00</td>
</tr>
<tr>
<td>Ísland</td>
<td>Vistor hf.</td>
<td>Sími: +354 535 7000</td>
</tr>
<tr>
<td>Italia</td>
<td>Sanofi S.r.l.</td>
<td>Tel: 800536389</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Swixx Biopharma s.r.o.</td>
<td>Tel: +421 2 208 33 600</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Sanofi Oy</td>
<td>Pub/Tel: + 358 201 200 300</td>
</tr>
<tr>
<td>Sverige</td>
<td>Sanofi AB</td>
<td>Tel: +46 (0)8 634 50 00</td>
</tr>
</tbody>
</table>
This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.

The following information is intended for healthcare professionals only:

Instructions for use – reconstitution, dilution and administration

The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride solution for injection and then administered by intravenous infusion.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage and conditions are the responsibility of the user. The reconstituted solution cannot be stored and should be promptly diluted; only the diluted solution can be held for up to 24 hours at 2°C -8°C.

Use aseptic technique

1. The number of vials should be determined to be reconstituted based on the individual patient's weight and the required vials should be removed from the refrigerator in order to allow them to reach room temperature (in approximately 30 minutes). Each vial of Fabrazyme is intended for single use only.

Reconstitution

2. Each vial of Fabrazyme 5 mg has to be reconstituted with 1.1 ml water for injections. Forceful impact of the water for injections on the powder and foaming should be avoided. This is done by slow drop-wise addition of the water for injection down the inside of the vial and not directly onto the lyophilisate. Each vial should be rolled and tilted gently. The vial should not be inverted, swirled or shaken.

3. The reconstituted solution contains 5 mg agalsidase beta per ml, and appears as a clear colourless solution. The pH of the reconstituted solution is approximately 7.0. Before further dilution, the reconstituted solution in each vial should be visually inspected for particulate matter and discoloration. The solution should not be used if foreign particles are observed or if the solution is discoloured.

4. After reconstitution it is recommended to promptly dilute the vials, to minimise protein particle formation over time.

5. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
**Dilution**

6. Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride solution for injection, from the infusion bag.

7. The airspace within the infusion bag should be removed to minimise the air/liquid interface.

8. 1.0 ml (equal to 5 mg) of the reconstituted solution from each vial up to the total volume required should be slowly withdrawn for the patient dose. Filter needles should not be used and foaming should be avoided.

9. The reconstituted solution should slowly be injected directly into the 0.9% sodium chloride solution for injection (not in any remaining airspace) to a final concentration between 0.05 mg/ml and 0.7 mg/ml. The total volume of sodium chloride 0.9% solution for infusion (between 50 and 500 ml) should be determined based on the individual dose. For doses lower than 35 mg a minimum of 50 ml should be used, for doses 35 to 70 mg a minimum of 100 ml should be used, for doses 70 to 100 mg a minimum of 250 ml should be used and for doses greater than 100 mg only 500 ml should be used. The infusion bag should be gently inverted or lightly massaged to mix the diluted solution. The infusion bag should not be shaken or excessively agitated.

**Administration**

10. It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity. The initial IV infusion rate should be no more than 0.25 mg/min (15 mg/hour). The infusion rate may be slowed in the event of infusion-associated reactions.

    After patient tolerance is well established, the infusion rate may be increased in increments of 0.05 to 0.083 mg/min (increments of 3 to 5 mg/hr) with each subsequent infusion. In clinical trials with classic patients, the infusion rate was increased incrementally to reach a minimum of 2 hours. This was achieved after 8 initial infusions at 0.25 mg/min (15 mg/hr), without any IARs, change in infusion rate, or infusion interruption. A further decrease of infusion time to 1.5 hours was allowed for patients without new IARs during the last 10 infusions or reported serious adverse events within the last 5 infusions. Each rate increment of 0.083 mg/min (~5 mg/hr) was maintained for 3 consecutive infusions, without any new IARs, change in infusion rate, or infusion interruption, before subsequent rate increases.

    For patients weighing < 30 kg, the maximum infusion rate should remain at 0.25 mg/min (15 mg/hr).